Article info
Clinical science
Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial
- Correspondence to Dr Nikolas J S London, Retina Consultants San Diego, Poway, California 92064, USA; nik.london{at}gmail.com; Dr Richard S Kaiser, Mid Atlantic Retina, Philadelphia, Pennsylvania 19107, USA; richardskaisermd{at}gmail.com
Citation
Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial
Publication history
- Received July 4, 2018
- Revised October 7, 2018
- Accepted October 9, 2018
- First published October 31, 2018.
Online issue publication
August 23, 2019
Article Versions
- Previous version (31 October 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.